488 / 604
Phase II or retrospec+ve cohorts
Author; year
Design
Pts
Dose/frx
m-‐FU
Locol control
(%)
Survival 1,2
years
1, 2 years (%)
Wulf 2004
Dose esc.
41
3x10-‐12.5 Gy
1x26 Gy
9 mts
80
85, 33
Hof 2007
Phase I/II
61
1x12-‐30 Gy
14 mts
83
(>26 Gy and
<10cc)
78, 65
Rusthoven 2009 Phase I/II
38
3x16-‐20 Gy
15 mts
96
65, 39
Zhang 2011
Retrospect
71
3-‐5x12 Gy
25 mts
97, 89
79, 41 (3 yr)
Ricardi 2012
Retrospect
61
1x26 Gy,
3x15 Gy,
4x9 Gy
20 mts
89
79, 67
Comito 2014
Phase II
40
4x12 –
3x25 Gy
24
80
80, 65
DeVin 2014
Retrospect
56
10x4-‐5 Gy
12 mts
33
(incl brain)
55 (2 yr)
Takahachi 2014 Carbon ions
Feasibility
34
12x5 Gy
1x44 Gy
24 mts
85
90, 65
Fode 2015
Retrospect
92
3x15-‐22.5 Gy
29
LR: 13
80, 58
Guckenberger/
DEGRO (abstract)
Retrospect
Mul+-‐inst
715
NA
NA
NA
53 (2 yr)
24 (5 yr)
Lung mets: Local control rates 80-‐96%